Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline

Prica, Anca; Baldassarre, Fulvia; Hicks, Lisa K.; Imrie, Kevin; Kouroukis, Tom; Cheung, Matthew C.

doi:10.1016/j.clon.2016.09.004

Cited by 16 publications

(15 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For treatment of these malignancies, rituximab-containing regimens are recommended. [63,64] When rituximab is used in combination with fludarabine, attention should be paid to the effects of renal insufficiency on fludarabine excretion. Approximately 60% of an administered dose of fludarabine is excreted in the urine within 24 h, so its dosage needs to be reduced when GFR is less than 70 mL/min, and it should be avoided to use in renal failure.…”

Section: Treatment Regimens: For Cryo Vas and Glomerulonephritismentioning

confidence: 99%

Cryoglobulinemic vasculitis and glomerulonephritis

Chen

Cheng

Rui

et al. 2019

Chinese Medical Journal

View full text Add to dashboard Cite

Objective:Cryoglobulinemia often causes systemic vasculitis, thereby damaging to skin and internal organs including kidneys, even life-threatening. This review aimed to introduce the advances in understanding, detection, and treatment of this disease in recent years, with a particular concern to clinical practice.Data sources:All the data in this review were from the English or Chinese literature in the PubMed and China National Knowledge Infrastructure databases as of March 2019.Study selection:This review selected important original articles, meaningful reviews, and some reports on cryoglobulinemia published in recent years and in history, as well as the guidelines for treatment of underlying diseases which lead to cryoglobulinemia.Results:Diagnosis of cryoglobulinemia relies on serum cryoglobulin test, in which to ensure that the blood sample temperature is not less than 37°C in the entire pre-analysis phase is the key to avoid false negative results. Cryoglobulinemic vasculitis (Cryo Vas), including cryoglobulinemic glomerulonephritis (Cryo GN), usually occurs in types II and III mixed cryoglobulinemia, and can also be seen in type I cryoglobulinemia caused by monoclonal IgG3 or IgG1. Skin purpura, positive serum rheumatoid factor, and decreased serum levels of C4 and C3 are important clues for prompting types II and III Cryo Vas. Renal biopsy is an important means for diagnosis of Cryo GN, while membranous proliferative GN is the most common pathological type of Cryo GN. In recent years, great advances have been made in the treatment of Cryo Vas and its underlying diseases, and this review has briefly introduced these advances.Conclusions:Laboratory examinations of serum cryoglobulins urgently need standardization. The recent advances in the diagnosis and treatment of Cryo Vas and GN need to be popularized among the clinicians in related disciplines.

show abstract

Section: Treatment Regimens: For Cryo Vas and Glomerulonephritismentioning

confidence: 99%

Cryoglobulinemic vasculitis and glomerulonephritis

Chen

Cheng

Rui

et al. 2019

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…Rituximab is widely used for the treatment of B cell non-Hodgkin lymphoma, being a key component of most therapeutic regimens [1][2][3][4] . The 375 mg/m 2 intravenous (iv) formulation involves dose calculations, infusion preparation, a long infusion duration, and titration of the infusion rate according to tolerability 5 .…”

Section: Introductionmentioning

confidence: 99%

Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres

et al. 2020

View full text Add to dashboard Cite

Results of studies comparing subcutaneous (sc) with intravenous (iv) rituximab indicate that the two formulations are comparable in efficacy, but most patients and health care professionals prefer the sc route, commonly because of shorter chair time and reduced risk of infusion-related reactions. Recent Canadian data, including those from the scuba study reported here, support the results of earlier international studies showing a reduction in preparation and administration time with the sc formulation, lower cost of administration, and reduced drug wastage because of the fixed sc dosing. Given the significant time and cost savings of the sc formulation, that formulation is generally preferred over the iv formulation for the treatment of follicular lymphoma, diffuse large B cell lymphoma, and chronic lymphocytic leukemia.

show abstract

“…Ритуксимаб является химерным моноклональным мышиным антителом против CD20. Обоснованность его включения в стандартные схемы комбинированной терапии лимфомы и хронического лимфоцитарного лейкоза доказана многими исследованиями [1]. Установлено, что добавление ритуксимаба к стандартной терапии значительно увеличивает выживаемость [2,3].…”

Section: Introductionunclassified

Comparative efficacy of chronic lymphocytic leukemia treatment with or without rituximab

2019

View full text Add to dashboard Cite

Контакты: Елена Андреевна Зенкова EAZenkova@mail.ru Введение. Моноклональные антитела -современные препараты для лечения хронического лимфоцитарного лейкоза. Цель исследования -сравнительное изучение эффективности добавления моноклонального антитела ритуксимаба (режим RFC) к режиму циклофосфамид + флударабин (режим FC) в терапии хронического лимфолейкоза. Материалы и методы. Ретроспективное исследование проведено на базе Клинической медико-санитарной части № 1 г. Перми. Проанализирован ответ на фармакотерапию всего у 22 пациентов (по 11 пациентов с режимами терапии FC и RFC). Результаты. Добавление ритуксимаба к режиму терапии FC позволило снизить число лимфоцитов ниже 4 × 10 9 / л уже после 1-го курса при сохранении уровня нейтрофилов выше 1,5 × 10 9 / л, отсутствии анемии (уровень гемоглобина >130 г / л) и тромбоцитопении (количество тромбоцитов >100 × 10 9 / л). Дополнительная оценка уровней креатинина и мочевой кислоты показала отсутствие синдрома лизиса опухоли на фоне режима RFC. Заключение. Включение ритуксимаба (RFC) в схему терапии циклофосфамид + флударабин (FC) позволяет получить более быстрый ответ на лечение при отсутствии нежелательных токсических явлений в виде влияния на функциональную активность костного мозга и синдрома лизиса опухоли. Ключевые слова: хронический лимфолейкоз, ритуксимаб, ответ на терапию, число лимфоцитов, синдром лизиса опухоли Для цитирования: Зенкова Е. А., Кугушев Е. Э., Васильева Э. Р. Сравнительная эффективность добавления ритуксимаба в схему лечения хронического лимфоцитарного лейкоза. Background. Monoclonal antibodies are modern drugs for the treatment of chronic lymphocytic leukemia.The objective is a comparative study of the monoclonal antibody rituximab efficacy when added to cyclophosphamide + fludarabine (RFC versus FC regimen) in the treatment of chronic lymphocytic leukemia. Materials and methods. A retrospective study was conducted in Clinical Medical Unit No. 1 of Perm. In total, the response to treatment was analyzed in 22 patients (11 patients in each group (FC and RFC therapy)). Results. Adding rituximab to the FC treatment regimen reduced the number of lymphocytes below 4 × 10 9 / L after the 1st course, while maintaining the neutrophil level above 1.5 × 10 9 / L, the absence of anemia (hemoglobin level >130 g / L) and thrombocytopenia (platelet count > 100 × 10 9 / L). An additional assessment of creatinine and uric acid levels showed the absence of tumor lysis syndrome during RFC therapy.Conclusion. The addition of rituximab (RFC therapy) to cyclophosphamide + fludarabine (FC therapy) provides a more rapid therapy response without adverse toxic effects such as impact on bone marrow functional activity and tumor lysis syndrome.

show abstract

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline

Cited by 16 publications

References 52 publications

Cryoglobulinemic vasculitis and glomerulonephritis

Cryoglobulinemic vasculitis and glomerulonephritis

Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres

Comparative efficacy of chronic lymphocytic leukemia treatment with or without rituximab

Contact Info

Product

Resources

About